Dance Biopharm has announced a name change, saying that the company will now be known as Aerami Therapeutics. The company, which is developing the Dance 501 insulin SMI, said that it is also moving its headquarters from San Francisco, CA to Durham, NC, USA and is expanding its pipeline.
The company recently presented results from the Phase 2 SAMBA 04 study of Dance 501 at the annual meeting of the American Diabetes Association. According to the announcement, Aerami intends to add several inhaled endocrinology therapies to its pipeline, noting “Each of these programs could enter clinical development in 2020, subject to our ability to obtain additional funding.”
Aerami CEO Anne Whitaker commented, “We are proud to launch Aerami, which is derived from a combination of Greek and Latin words. ‘Aero’ means air/wind and ‘ami’ means friend/friendly. The new brand reflects our commitment to provide patients living with chronic diseases, a patient-friendly alternative to routine injections, with our gentle mist inhaler. Our initial focus going forward is on rare and severe diseases in the endocrinology, respiratory and cardiovascular space. We have launched new pipeline programs in hypoparathyroidism and human growth hormone deficiency, which could benefit from the frequent pulsatile administration of inhaled parathyroid hormone and HGH, respectively, afforded by our smart inhaler. In addition, we are targeting advancing our inhalable pre-meal GLP-1 receptor agonist into the clinic in 2020, subject to additional funding, for treatment of type 2 diabetes patients who are not meeting their HbA1c goals with their current oral anti-diabetic treatments.”
Read the Aerami Therapeutics press release.
